Danish provider of clinical diagnostic tests BioPorto, has finalized a distribution deal with Simens Healthcare for delivery of a NGAL test adapted for Siemens Healthcare BN II and BN ProSpec Systems.
According to the press release, this customized NGAL test has now been tested and approved for final use on Siemens Healthcare’s BN II and BN ProSpec Systems.
BioPorto further said that the agreement has seen its first action, as Siemens Healthcare has placed its first order with BioPortoand. That means the cooperation enters into the next phase, where Siemens Healthcare will distribute the customized test for those machines, BioPorto said.
BioPorto’s CEO Peter Morch Eriksen said: “We are very pleased that the Siemens collaboration has reached the next stage. The Siemens agreement has a significant strategic importance for both knowledge of and the availability of NGAL as a biomarker. It is therefore an important event that Siemens has initiated the process.”